Jump to ContentJump to Main Navigation
Dementia with Lewy Body and Parkinson's Disease PatientsPatient, Family, and Clinician Working Together for Better Outcomes$
Users without a subscription are not able to see the full content.

J. Eric Ahlskog

Print publication date: 2013

Print ISBN-13: 9780199977567

Published to Oxford Scholarship Online: November 2020

DOI: 10.1093/oso/9780199977567.001.0001

Show Summary Details
Page of

PRINTED FROM OXFORD SCHOLARSHIP ONLINE (oxford.universitypressscholarship.com). (c) Copyright Oxford University Press, 2021. All Rights Reserved. An individual user may print out a PDF of a single chapter of a monograph in OSO for personal use. date: 20 June 2021

Are There Medications for Slowing Disease Progression?

Are There Medications for Slowing Disease Progression?

(p.19) 3 Are There Medications for Slowing Disease Progression?
Dementia with Lewy Body and Parkinson's Disease Patients

J. Eric Ahlskog

Oxford University Press

If diagnosed with dementia with Lewy bodies (DLB) or Parkinson’s disease, one would naturally want to do everything possible to halt or at least slow the disease progression. Are there medications for this purpose? Unfortunately, no controlled trials have analyzed this question among people with DLB. On the other hand, multiple randomized clinical trials have assessed a variety of drugs as possible agents to slow the progression of another Lewy disorder, Parkinson’s disease. If a strategy were available to slow the progression of Parkinson’s disease, that could be relevant to all Lewy conditions. Major clinical trials assessing drugs to slow the progression of Parkinson’s disease date back to the 1980s. In each of these trials hundreds of Parkinson’s disease patients from multiple participating medical centers were enrolled and randomized to either the study drug or a placebo. Drugs that have been investigated included high doses of vitamin E; the monoamine oxidase B (MAO-B) inhibitor selegiline (deprenyl); the dopamine agonists pramipexole and ropinirole; as well as two experimental agents shown in animals to reduce apoptosis (a cell death process that might be relevant to neurodegeneration). Unfortunately, none of these large trials provided compelling evidence for slowing the progression of Parkinson’s disease. The studies’ results were either negative or so confounded and inconclusive that a meaningful interpretation could not be drawn. Most recently, the newer MAO-B inhibitor rasagiline (which also reduces apoptosis) was similarly assessed in two large clinical trials. The outcomes from these rasagiline studies were mixed and difficult to interpret. A U.S. Food and Drug Administration (FDA) Advisory Panel concluded that there was insufficient evidence to conclude that rasagiline has disease-slowing properties. What confounded these outcomes (as well as some of the earlier trials) was that the study drug also had symptomatic benefits (i.e., treated Parkinson’s disease symptoms). Since the outcome measures were clinical assessments of parkinsonism, it was difficult to distinguish symptomatic benefit from slowed disease progression. Other drugs that have been studied as potential agents to slow the progression of Parkinson’s disease include creatine (used by muscle builders) and the antibiotic minocycline.

Keywords:   aerobic exercise, brain neuroplasticity, creatine, dopamine agonists, minocycline, monoamine oxidase B (MAO-B) inhibitors, pramipexole (Mirapex), rasagiline (MAO-B inhibitor), selegiline (deprenyl) (MAO-B inhibitor)

Oxford Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs , and if you can't find the answer there, please contact us .